The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

affibody.com

Founded Year

1998

Stage

Other Investors | Alive

About Affibody

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing biotherapeutics based on its unique proprietary technology platforms: Affibody molecules and Albumod. The company is based in Solna, Sweden.

Affibody Headquarter Location

Voltavagen 13

161 02,

Sweden

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Affibody Patents

Affibody has filed 49 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Proteins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/28/2016

10/26/2021

Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Monoclonal antibodies for tumors

Grant

Application Date

10/28/2016

Grant Date

10/26/2021

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Monoclonal antibodies for tumors

Status

Grant

Latest Affibody News

  • When was Affibody founded?

    Affibody was founded in 1998.

  • What is Affibody's latest funding round?

    Affibody's latest funding round is Other Investors.

  • Who are the investors of Affibody?

    Investors of Affibody include Life Equity Sweden, Permira, AP Fonden 3, GZ Group, SV Health Investors and 5 more.

  • Who are Affibody's competitors?

    Competitors of Affibody include Elusys Therapeutics, Acumen Pharmaceuticals, Athersys, Elcelyx Therapeutics, Arcion Therapeutics and 13 more.

You May Also Like

A
AutekBio

AutekBio is a biotech firm headquartered in the Bay Area, US.

u
ugichem

ugichem is developing antisense drugs based on its proprietary Ugimer platform for unmet medical needs in immune-mediated inflammatory diseases (IMID). Ugimers overcome the shortcomings of standard antisense technologies or RNAi. In contrast, Ugimers are not derived from natural nucleic acids but are based on the peptide nucleic acid (PNA) backbone and carry specific side chains for improved delivery, efficacy and specificity. This innovative design provides Ugimers with unique biopharmaceutical properties allowing them access to previously inaccessible organs, cells and cellular compartments, including the immune system. Moreover, Ugimers are the first and only antisense drugs that have efficacy in mitochondria.

E
Elara Pharmaceuticals

Elara Pharmaceuticals is a Heidelberg, Germany-based biotech company focused on the development of drugs for the treatment of different cancers.

S
Sonexa Therapeutics

Sonexa Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer's disease. ST101, the company's lead compound, represents an agent that, in animal models, has demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. ST101 has completed Phase I studies in both healthy volunteers and AD patients. It is being evaluated in Phase II Proof-of-Concept trials.

N
Nano Carrier

Nano Carrier is a biotech company using nanotechnology to improve patient Quality of Life with a focus on cancer.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.